Fracture healing with alendronate treatment in the Brtl/ plus mouse model of osteogenesis imperfecta

被引:19
|
作者
Meganck, J. A. [1 ,2 ]
Begun, D. L. [1 ,2 ]
McElderry, J. D. [3 ]
Swick, A. [1 ,2 ]
Kozloff, K. M. [1 ,2 ]
Goldstein, S. A. [1 ,2 ]
Morris, M. D. [3 ]
Marini, J. C. [4 ]
Caird, M. S. [1 ]
机构
[1] Univ Michigan, Dept Orthopaed Surg, Orthopaed Res Labs, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA
[4] NICHHD, Bone & Extracellular Matrix Branch, NIH, Bethesda, MD 20892 USA
基金
美国国家科学基金会; 美国国家卫生研究院;
关键词
Osteogenesis imperfecta; Bisphosphonates; Bone; Rodent; Fracture repair; HYPERPLASTIC CALLUS FORMATION; POLARIZED-LIGHT MICROSCOPY; ZOLEDRONIC ACID; BISPHOSPHONATE INCADRONATE; BONE STRENGTH; CHILDREN; PAMIDRONATE; COLLAGEN; REPAIR; RATS;
D O I
10.1016/j.bone.2013.06.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Osteogenesis imperfecta (OI) is a heritable bone dysplasia characterized by increased skeletal fragility. Patients are often treated with bisphosphonates to attempt to reduce fracture risk. However, bisphosphonates reside in the skeleton for many years and long-term administration may impact bone material quality. Acutely, there is concern about risk of non-union of fractures that occur near the time of bisphosphonate administration. This study investigated the effect of alendronate, a potent aminobisphosphonate, on fracture healing. Using the Brtl/+ murine model of type IV OI, tibial fractures were generated in 8-week-old mice that were untreated, treated with alendronate before fracture, or treated before and after fracture. After 2, 3, or 5 weeks of healing, tibiae were assessed using microcomputed tomography (mu CT), torsion testing, quantitative histomorphometry, and Raman microspectroscopy. There were no morphologic, biomechanical or histomorphometric differences in callus between untreated mice and mice that received alendronate before fracture. Alendronate treatment before fracture did not cause a significant increase in cartilage retention in fracture callus. Both Brtl/+ and WT mice that received alendronate before and after fracture had increases in the callus volume, bone volume fraction and torque at failure after 5 weeks of healing. Raman microspectroscopy results did not show any effects of alendronate in wild-type mice, but calluses from Brtl+ mice treated with alendronate during healing had a decreased mineral-to-matrix ratio, decreased crystallinity and an increased carbonate-to-phosphate ratio. Treatment with alendronate altered the dynamics of healing by preventing callus volume decreases later in the healing process. Fracture healing in Brtl/+ untreated animals was not significantly different from animals in which alendronate was halted at the time of fracture. (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码:204 / 212
页数:9
相关论文
共 50 条
  • [1] Increased susceptibility to microdamage in Brtl/+ mouse model for osteogenesis imperfecta
    Davis, Mathieu S.
    Kovacic, Bethany L.
    Marini, Joan C.
    Shih, Albert J.
    Kozloff, Kenneth M.
    BONE, 2012, 50 (03) : 784 - 791
  • [2] Sclerostin Antibody Improves Skeletal Parameters in a Brtl/+ Mouse Model of Osteogenesis Imperfecta
    Sinder, Benjamin P.
    Eddy, Mary M.
    Ominsky, Michael S.
    Caird, Michelle S.
    Marini, Joan C.
    Kozloff, Kenneth M.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2013, 28 (01) : 73 - 80
  • [3] Comparable outcomes in fracture reduction and bone properties with RANKL inhibition and alendronate treatment in a mouse model of osteogenesis imperfecta
    Bargman, R.
    Posham, R.
    Boskey, A. L.
    DiCarlo, E.
    Raggio, C.
    Pleshko, N.
    OSTEOPOROSIS INTERNATIONAL, 2012, 23 (03) : 1141 - 1150
  • [4] Rapidly growing Brtl/ plus mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment
    Sinder, Benjamin P.
    Salemi, Joseph D.
    Ominsky, Michael S.
    Caird, Michelle S.
    Marini, Joan C.
    Kozloff, Kenneth M.
    BONE, 2015, 71 : 115 - 123
  • [5] Modeling anabolic and antiresorptive therapies for fracture healing in a mouse model of osteogenesis imperfecta
    O'Donohue, Alexandra K.
    Dao, Aiken
    Bobyn, Justin D.
    Munns, Craig F.
    Little, David G.
    Schindeler, Aaron
    JOURNAL OF ORTHOPAEDIC RESEARCH, 2023, 41 (04) : 808 - 814
  • [6] Cortical bone properties in the Brtl/ plus mouse model of Osteogenesis imperfecta as evidenced by acoustic transmission microscopy
    Blouin, S.
    Fratzl-Zelman, N.
    Roschger, A.
    Cabral, W. A.
    Klaushofer, K.
    Marini, J. C.
    Fratzl, P.
    Roschger, P.
    JOURNAL OF THE MECHANICAL BEHAVIOR OF BIOMEDICAL MATERIALS, 2019, 90 : 125 - 132
  • [7] Tissue level material composition and mechanical properties in Brtl/plus mouse model of Osteogenesis Imperfecta after sclerostin antibody treatment
    Lloyd, William R.
    Sinder, Benjamin P.
    Salemi, Joseph
    Ominsky, Michael S.
    Marini, Joan C.
    Caird, Michelle S.
    Morris, Michael D.
    Kozloff, Kenneth M.
    PHOTONIC THERAPEUTICS AND DIAGNOSTICS XI, 2015, 9303
  • [8] Early Fracture Healing is Delayed in the Col1a2+/G610C Osteogenesis Imperfecta Murine Model
    Besio, Roberta
    Maruelli, Silvia
    Battaglia, Severine
    Leoni, Laura
    Villani, Simona
    Layrolle, Pierre
    Rossi, Antonio
    Trichet, Valerie
    Forlino, Antonella
    CALCIFIED TISSUE INTERNATIONAL, 2018, 103 (06) : 653 - 662
  • [9] Comparable Effects of Strontium Ranelate and Alendronate Treatment on Fracture Reduction in a Mouse Model of Osteogenesis Imperfecta
    Shi, Changgui
    Sun, Bin
    Ma, Chao
    Wu, Huiqiao
    Chen, Rui
    He, Hailong
    Zhang, Ying
    BIOMED RESEARCH INTERNATIONAL, 2021, 2021
  • [10] A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta
    Camacho, NP
    Raggio, CL
    Doty, SB
    Root, L
    Zraick, V
    Ilg, WA
    Toledano, TR
    Boskey, AL
    CALCIFIED TISSUE INTERNATIONAL, 2001, 69 (02) : 94 - 101